A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Launched by PFIZER · May 19, 2025
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
The BRANCH-HF clinical trial is studying a new medicine called PF-07328948 to see how safe it is and how well it works for treating heart failure in adults. Heart failure is a condition where the heart struggles to pump enough blood to meet the body's needs. This study is looking for adults aged 18 and older who have been diagnosed with heart failure for at least three months and have certain symptoms. To participate, you should have a heart function that is still above a certain level and be able to walk a minimum distance in six minutes.
If you decide to join the trial, you'll be part of an important effort to help improve treatments for heart failure. The study is not yet recruiting, so it’s a good time to learn more about it. Keep in mind, there are some health conditions that might prevent you from participating, like having certain types of diabetes or liver issues. This trial is a chance to contribute to research that may benefit many people with heart failure in the future.
Gender
ALL
Eligibility criteria
- This study is seeking participants who are:
- Key Inclusion Criteria include:
- • aged 18 years or older.
- • - clinically confirmed to have a diagnosis of heart failure for at least 3 months
- • New York Heart Association Class II-IV symptoms
- • left ventricular ejection fraction greater than 40%
- • Body mass index of 27 kg/m2 or higher
- • Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score \< 85
- • Six-minute walking distance greater than 75 meters
- Key Exclusion Criteria include:
- • Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body.
- • Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor.
- • History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes
- • Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mckinney, Texas, United States
Yokohama, Kanagawa, Japan
Meguro Ku, Tokyo, Japan
Sapporo, Hokkaido, Japan
Tomball, Texas, United States
Sendai, Miyagi, Japan
Toshima Ku, Tokyo, Japan
Brownsville, Texas, United States
Tsu, Mie, Japan
Hazel Crest, Illinois, United States
Kasugai, Aichi, Japan
Sagamihara, Kanagawa, Japan
Matsudo, Chiba, Japan
Boca Raton, Florida, United States
Iwakuni, Yamaguchi, Japan
Toshimaku, Tokyo, Japan
Trois Rivieres, Quebec, Canada
Wako, Saitama, Japan
Beverly Hills, California, United States
Lake Forest, California, United States
Brownsville, Texas, United States
North Miami Beach, Florida, United States
Lincoln, Nebraska, United States
Yokohama, Kanagawa, Japan
Sapporo, Tokyo, Japan
Suginami, Tokyo, Japan
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported